UPDATE: Deutsche Bank Raises PT to $15 on Inhibitex

A report from Deutsche Bank reiterates its Buy rating and raises its price target to $15 on Inhibitex

. The report states, “Eventful Q3 call with 200mg dose reduction of -4.25 logs. They have $54M in cash and INHX projects they have enough cash until Q1 2013. We have updated our model for increased market share due to promising 7 day data. Key catalysts include 7 day data for on-going 100mg +ribavirn study and Phase 2 genotype 2/3 4 week data in 1Q1." INHX closed Friday at $8.54.